Free Trial

SI-BONE (SIBN) Competitors

SI-BONE logo
$13.80
+0.63 (+4.78%)
(As of 10/31/2024 ET)

SIBN vs. SRDX, OFIX, ANIK, CRY, MDXG, CNMD, SLNO, NVCR, RXST, and WRBY

Should you be buying SI-BONE stock or one of its competitors? The main competitors of SI-BONE include Surmodics (SRDX), Orthofix Medical (OFIX), Anika Therapeutics (ANIK), CryoLife (CRY), MiMedx Group (MDXG), CONMED (CNMD), Soleno Therapeutics (SLNO), NovoCure (NVCR), RxSight (RXST), and Warby Parker (WRBY). These companies are all part of the "medical" sector.

SI-BONE vs.

Surmodics (NASDAQ:SRDX) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, profitability, analyst recommendations, earnings, dividends, community ranking, risk and media sentiment.

Surmodics received 172 more outperform votes than SI-BONE when rated by MarketBeat users. However, 67.90% of users gave SI-BONE an outperform vote while only 63.95% of users gave Surmodics an outperform vote.

CompanyUnderperformOutperform
SurmodicsOutperform Votes
337
63.95%
Underperform Votes
190
36.05%
SI-BONEOutperform Votes
165
67.90%
Underperform Votes
78
32.10%

Surmodics has higher earnings, but lower revenue than SI-BONE. Surmodics is trading at a lower price-to-earnings ratio than SI-BONE, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Surmodics$120.82M4.43-$1.54M-$0.10-375.20
SI-BONE$150.71M3.82-$43.34M-$1.09-12.66

Surmodics has a net margin of -1.16% compared to SI-BONE's net margin of -27.10%. Surmodics' return on equity of 3.88% beat SI-BONE's return on equity.

Company Net Margins Return on Equity Return on Assets
Surmodics-1.16% 3.88% 2.59%
SI-BONE -27.10%-24.27%-17.98%

In the previous week, SI-BONE had 1 more articles in the media than Surmodics. MarketBeat recorded 3 mentions for SI-BONE and 2 mentions for Surmodics. SI-BONE's average media sentiment score of 1.07 beat Surmodics' score of 0.62 indicating that SI-BONE is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Surmodics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
SI-BONE
1 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Surmodics currently has a consensus target price of $50.00, suggesting a potential upside of 33.26%. SI-BONE has a consensus target price of $22.67, suggesting a potential upside of 64.25%. Given SI-BONE's stronger consensus rating and higher probable upside, analysts clearly believe SI-BONE is more favorable than Surmodics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surmodics
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
SI-BONE
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Surmodics has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

96.6% of Surmodics shares are owned by institutional investors. Comparatively, 98.1% of SI-BONE shares are owned by institutional investors. 8.9% of Surmodics shares are owned by insiders. Comparatively, 5.4% of SI-BONE shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

SI-BONE beats Surmodics on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SIBN vs. The Competition

MetricSI-BONESurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$575.38M$4.51B$5.36B$8.41B
Dividend YieldN/A43.24%5.22%4.20%
P/E Ratio-13.6633.23131.5917.70
Price / Sales3.8267.621,438.8478.39
Price / CashN/A47.9839.0633.56
Price / Book3.304.524.744.57
Net Income-$43.34M$13.97M$115.35M$225.37M
7 Day Performance9.44%1.16%-0.83%-0.59%
1 Month Performance-1.29%1.08%3.63%1.51%
1 Year Performance-18.87%57.47%38.96%32.97%

SI-BONE Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SIBN
SI-BONE
4.241 of 5 stars
$13.80
+4.8%
$22.67
+64.3%
-20.2%$575.38M$150.71M-13.66350Positive News
SRDX
Surmodics
4.0122 of 5 stars
$37.68
+0.2%
$50.00
+32.7%
+29.6%$537.69M$132.58M-376.80376Analyst Forecast
News Coverage
OFIX
Orthofix Medical
1.2246 of 5 stars
$16.05
+1.1%
$20.00
+24.6%
+48.2%$602.34M$771.65M-5.031,634Upcoming Earnings
ANIK
Anika Therapeutics
4.2519 of 5 stars
$24.50
+0.7%
$30.50
+24.5%
+30.0%$357.38M$166.88M-4.83357News Coverage
Gap Down
CRY
CryoLife
1.5253 of 5 stars
N/AN/AN/A$703.22M$253.23M596.201,200
MDXG
MiMedx Group
4.0354 of 5 stars
$5.89
+0.7%
$12.00
+103.7%
-10.0%$869.39M$340.46M10.52870News Coverage
Gap Up
CNMD
CONMED
4.7643 of 5 stars
$62.91
+1.2%
$79.80
+26.8%
-33.1%$1.94B$1.28B20.044,000Earnings Report
Analyst Forecast
News Coverage
SLNO
Soleno Therapeutics
4.3095 of 5 stars
$56.29
+2.5%
$68.71
+22.1%
+140.7%$1.88BN/A-23.0730Upcoming Earnings
Analyst Forecast
NVCR
NovoCure
3.9607 of 5 stars
$17.31
+3.4%
$26.17
+51.2%
+30.1%$1.86B$549.96M-10.961,453Earnings Report
Analyst Forecast
News Coverage
RXST
RxSight
2.7123 of 5 stars
$50.31
-0.1%
$60.14
+19.5%
+144.9%$1.86B$89.08M-49.32220Upcoming Earnings
Analyst Forecast
Insider Selling
WRBY
Warby Parker
2.2546 of 5 stars
$17.40
+1.6%
$17.00
-2.3%
+29.5%$1.75B$669.77M-44.623,491Upcoming Earnings
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:SIBN) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners